结果显示,相较于安慰剂,达格列净可显著延缓 eGFR 降低,延缓 eGFR 慢性斜率差异为 1.95 mL/min/1.73 m2/年;达格列净降低 CKD 人群主要心肾复合终点(eGFR 持续下降 ≥ 50%,ESRD,肾病死亡或心血管死亡)风险 39%;安全性方面两组严重...
结果显示,相较于安慰剂,达格列净可显著延缓 eGFR 降低,延缓 eGFR 慢性斜率差异为 1.95 mL/min/1.73 m2/年;达格列净降低 CKD 人群主要心肾复合终点(eGFR 持续下降 ≥ 50%,ESRD,肾病死亡或心血管死亡)风险 39%;安全性方面两组严重不良事件发生率相似[3]。 EMPA-KIDNEY 研究纳入 CKD 患者 6,609 例,eGFR ≥...
对于CKD患者,无论是否伴有T2DM,且无论基线是否使用MRAs,达格列净均能显著降低主要和次要复合心肾终点的发生率,延缓eGFR下降,且安全性及耐受性良好。 达格列净对CKD患者血压的影响:DAPA-CKD研究的预设分析 研究背景 达格列净对于CKD患者...
In patients with CKD stage 4-5,dapagliflozinplus integrated CKD care improved total eGFR slope composite renal outcomes, composite renal andheart failureoutcomes, and renal and cardiovascular outcomes compared with CKD care alone. This is "the first SGLT2 inhibitor renal outcome trial to include pati...
结果eGFR MDRD高于eGFR CKD-EPI,均值差为4.33 ml·min -1· (1.73 m 2) -1,但两者评估eGFR值的相关性和一致性良好(Kappa值为0.749, r=0.991, P <0.05)。以MDRD为标准,CKD-EPI公式改变了152例(18.1%)患者的分期,其中9例(1.1%)分期上调,143例(17.0%)分期下调。全因死亡NRI为0.059( P<0.05),心血管死...
stage 1 CKD, 10,534 (25.6%) stage 2 CKD without proteinuria, 689 (1.7%) stage 2 CKD with proteinuria, 241 (0.6%) CKD stage 3A (eGFR 59-45mL/min per 1.73 m2) without proteinuria, 28 (0.1%) stage 3A with proteinuria and 37 (0.1%) with more advanced CKD defined as stages 3B and...
此外,在预先指定的亚组中,finerenone对主要结果的影响基本一致,包括基线估计的肾小球滤过率(eGFR)和尿白蛋白与肌酐比率(UACR)类别。该研究中,finerenone的耐受性良好,与先前研究中的安全性特征一致。 在关键3期FIDELIO-DKD研究的基础上,FIGARO-DKD研究增加了finerenone在更广泛患者群体中CV益处的重要证据。FIDELIO...
Patients with CKD stages 1-3 are generally asymptomatic. Typically, it is not until stages 4-5 (GFR < 30 mL/min/1.73 m²) that endocrine/metabolic derangements or disturbances in water or electrolyte balance become clinically manifest. Signs of metabolic acidosis in stage 5 CKD include the ...
. Do not code stages 1 or 2. Any patient with two or more creatinines producing an eGFR of < 60 should have their CKD stage coded and the Problem/Summary Page updated. Any patient suspected of having CKD 3 or worse should have an abdominal and cardiovascular examination, BP check, ...
KDOQI指南中CKD定义和分期的价值和争议[1]